GlobeImmune, Inc : GlobeImmune to Present at 12th Annual Needham Healthcare
LOUISVILLE, Colo., April 18, 2013 - GlobeImmune, Inc., today announced that
Timothy C. Rodell, M.D., president and chief executive officer of GlobeImmune,
will present at the 12th Annual Needham Healthcare Conference at 2:20 p.m. EDT
on Tuesday, April 30, at The Westin New York Grand Central Hotel in New York.
Dr. Rodell will provide an update on the company's Tarmogen^® platform and
product candidates, including GI-4000 for the treatment of Ras-mutated
cancers, GI-6207 for cancers expressing carcinoembryonic antigen (CEA),
GI-6301 for cancers expressing the brachyury protein and GI-13020 for the
treatment of chronic hepatitis B infection.
GlobeImmune is a biopharmaceutical company focused on developing products for
the treatment of cancer and infectious diseases based on its proprietary
Tarmogen platform. Tarmogens activate the immune system by stimulating
cellular immunity, known as T cell immunity, in contrast to traditional
vaccines that predominately stimulate antibody production. To date, Tarmogen
product candidates have been generally well tolerated in clinical trials for
multiple disease indications and are efficient to manufacture. In May 2009,
the company entered into a collaboration agreement with Celgene Corporation
focused on the discovery, development and commercialization of product
candidates for the treatment of cancer. In October 2011, the company entered
into a worldwide, strategic collaboration with Gilead Sciences, Inc., to
develop Tarmogens for the treatment of chronic hepatitis B infection. For
additional information, please visit the company's website at
Senior Director Corporate Development
S.A. Noonan Communications, LLC
Lena Evans or Tony Russo, Ph.D.
Russo Partners, LLC
T: 212-845-4262 or 212-845-4251
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: GlobeImmune, Inc via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.